rHIV7-shI-TAR-CCR5RZ-transduced Hematopoietic Stem/Progenitor Cells

also known as Base-edited hematopoietic stem and progenitor cells · CD34 cells · CLBS119 · CLBS12 · CLBS14 · CLBS201 · Cultured retinal stem and progenitor cells · Genetically Engineered Hematopoietic Stem/Progenitor Cells · +3 more

targets CD40LG, CYBB, FANCA, IL2RG via restoration

Developed for: acute myocardial infarction · age-related macular degeneration · arteriosclerosis obliterans · chronic kidney disease · COVID-19 · Fanconi anemia · granulomatous disease, chronic, X-linked · HIV infectious disease
+7 more
· hyper-IgM syndrome type 1 · limb ischemia · myocardial ischemia · rotator cuff syndrome · T-B+ severe combined immunodeficiency due to gamma chain deficiency · thromboangiitis obliterans · non-Hodgkin lymphoma
Investigated by: Lisata Therapeutics, Inc. · National Institute of Allergy and Infectious Diseases (NIAID) · Belarusian State Medical University · Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT) · Centro de Investigación en Red de Enfermedades Raras (CIBERER) · City of Hope Medical Center
+10 more
· Hospital Infantil Universitario Niño Jesús, Madrid, Spain · Hospital Vall d'Hebron · Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus · Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz · National Cancer Institute (NCI) · National Center of Blood Transfusion Mexico. · National Heart Institute, Mexico · Second Affiliated Hospital, School of Medicine, Zhejiang University · Universitaire Ziekenhuizen KU Leuven · Universitat Autonoma de Barcelona

Trials 13 · a red edge is where a trial was stopped

today NCT07320378 · Ph 0 NCT06959771 · Ph 1/2 NCT06851767 · Ph 1/2 NCT06325709 · Ph 1/2 NCT05187104 · Ph 1/2 NCT04990427 · Ph 1 NCT04522817 · Ph 1 NCT02501018 · Ph 2 NCT03157804 · Ph 1/2 NCT02337985 · Ph 1 NCT02437708 · Ph 3 NCT00725738 · Ph 2/3 NCT00300053 · Ph 2

200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029203020312032203320342035

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT07320378	May 2026 → Jun 2028 expected	rotator cuff syndrome	Second Affiliated Hospital, School of Medicine, Zhejiang University	Not yet recruiting	No outcome recorded
Phase 13 trials
Phase 1	NCT04990427	Jan 2022 → Jan 2023	chronic kidney disease	Lisata Therapeutics, Inc.	Completed	No outcome recorded
Phase 1	NCT04522817	Oct 2020 → May 2021	COVID-19	Lisata Therapeutics, Inc.	Withdrawn	No outcome recorded
Phase 1	NCT02337985	Nov 2015 → Sep 2026 expected	Burkitt lymphoma, HIV infectious disease, plasmablastic lymphoma, primary effusion lymphoma	City of Hope Medical Center	Active not recruiting	No outcome recorded
Phase 1/25 trials
Phase 1/2	NCT06959771	Jul 2025 → Oct 2027 expected	hyper-IgM syndrome type 1	National Institute of Allergy and Infectious Diseases (NIAID)	Recruiting	No outcome recorded
Phase 1/2	NCT06851767	May 2025 → Dec 2034 expected	T-B+ severe combined immunodeficiency due to gamma chain deficiency	National Institute of Allergy and Infectious Diseases (NIAID)	Enrolling by invitation	No outcome recorded
Phase 1/2	NCT06325709	Apr 2024 → Dec 2032 expected	granulomatous disease, chronic, X-linked	National Institute of Allergy and Infectious Diseases (NIAID)	Recruiting	No outcome recorded
Phase 1/2	NCT05187104	Mar 2022 → Dec 2023	age-related macular degeneration	Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus	Unknown	No outcome recorded
Phase 1/2	NCT03157804	Jan 2016 → Apr 2019	Fanconi anemia	Hospital Infantil Universitario Niño Jesús, Madrid, Spain	Completed	No outcome recorded
Phase 22 trials
Phase 2	NCT02501018	Nov 2017 → May 2022	arteriosclerosis obliterans, limb ischemia, thromboangiitis obliterans	Lisata Therapeutics, Inc.	Completed	No outcome recorded
Phase 2	NCT00300053	Apr 2006 → Mar 2008	myocardial ischemia	Lisata Therapeutics, Inc.	Completed	No outcome recorded
Phase 2/31 trial
Phase 2/3	NCT00725738	May 2008 → Dec 2009	acute myocardial infarction	National Heart Institute, Mexico	Unknown	No outcome recorded
Phase 31 trial
Phase 3	NCT02437708	Sep 2014 → Aug 2019	—	Universitaire Ziekenhuizen KU Leuven	Completed	No outcome recorded

Evidence & citations 16 cited values

Every value below carries the sentence it was read from. 14 sources stand behind the page.

Field	Value	Cited text
Known as	rHIV7-shI-TAR-CCR5RZ-transduced Hematopoietic Stem/Progenitor Cells	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02337985 ↗
Known as	Base-edited hematopoietic stem and progenitor cells	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06851767 ↗ 2 NCT06959771 ↗ NCT06325709 ↗
Known as	CD34 cells	“about 1-2 million of CD34 cells” NCT00725738 ↗
Known as	CLBS119	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04522817 ↗
Known as	CLBS12	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02501018 ↗
Known as	CLBS14	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00300053 ↗
Known as	CLBS201	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04990427 ↗
Known as	Cultured retinal stem and progenitor cells	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05187104 ↗
Known as	Genetically Engineered Hematopoietic Stem/Progenitor Cells	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03157804 ↗
Known as	stem and progenitor cells	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02437708 ↗
Known as	Tendon stem/progenitor cells	“Therefore, this study intends to first culture and expand tendon stem/progenitor cells (TSPCs) to form therapeutic agents, then apply TSPC-enhanced therapy intraoperatively to...” NCT07320378 ↗
Known as	TSPCs	“Therefore, this study intends to first culture and expand tendon stem/progenitor cells (TSPCs) to form therapeutic agents, then apply TSPC-enhanced therapy intraoperatively to...” NCT07320378 ↗
Action	Restore	“in order to restore their hematopoiesis with genetically corrected stem cells” NCT03157804 ↗
Modality	Cell therapy	“Autologous CD34+ cell therapy was associated with persistent improvement in angina at 2 years” PMID 27151378 ↗ May 2016
Route	Other	“Autologous CD34+ cells will be delivered in 10 intramyocardial injections” NCT00300053 ↗
Target	FANCA	“lentiviral vector carrying the gene FANCA” NCT03157804 ↗